UCB Past Earnings Performance
Past criteria checks 1/6
UCB's earnings have been declining at an average annual rate of -17.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.4% per year. UCB's return on equity is 2.7%, and it has net margins of 4.4%.
Key information
-17.4%
Earnings growth rate
-17.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 1.4% |
| Return on equity | 2.7% |
| Net Margin | 4.4% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How UCB makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5,454 | 240 | 2,033 | 1,660 |
| 31 Mar 24 | 5,318 | 292 | 1,929 | 1,645 |
| 31 Dec 23 | 5,182 | 343 | 1,824 | 1,630 |
| 30 Jun 23 | 5,111 | 332 | 1,726 | 1,631 |
| 31 Mar 23 | 5,279 | 376 | 1,720 | 1,651 |
| 31 Dec 22 | 5,447 | 420 | 1,714 | 1,670 |
| 30 Jun 22 | 5,854 | 887 | 1,695 | 1,674 |
| 31 Mar 22 | 5,816 | 971 | 1,625 | 1,652 |
| 31 Dec 21 | 5,777 | 1,055 | 1,554 | 1,629 |
| 30 Sep 21 | 5,647 | 996 | 1,506 | 1,631 |
| 30 Jun 21 | 5,517 | 936 | 1,458 | 1,633 |
| 31 Mar 21 | 5,432 | 834 | 1,438 | 1,601 |
| 31 Dec 20 | 5,347 | 732 | 1,417 | 1,569 |
| 30 Jun 20 | 5,198 | 743 | 1,368 | 1,393 |
| 31 Mar 20 | 5,056 | 767 | 1,336 | 1,333 |
| 31 Dec 19 | 4,913 | 790 | 1,303 | 1,272 |
| 30 Jun 19 | 4,686 | 652 | 1,212 | 1,229 |
| 31 Mar 19 | 4,659 | 722 | 1,178 | 1,195 |
| 31 Dec 18 | 4,632 | 792 | 1,144 | 1,161 |
| 30 Jun 18 | 4,569 | 872 | 1,105 | 1,083 |
| 31 Mar 18 | 4,522 | 812 | 1,119 | 1,070 |
| 31 Dec 17 | 4,474 | 752 | 1,132 | 1,057 |
| 30 Sep 17 | 4,400 | 708 | 1,138 | 1,047 |
| 30 Jun 17 | 4,325 | 664 | 1,144 | 1,036 |
| 31 Mar 17 | 4,236 | 604 | 1,133 | 1,028 |
| 31 Dec 16 | 4,147 | 543 | 1,122 | 1,020 |
| 30 Sep 16 | 4,051 | 439 | 1,111 | 1,022 |
| 30 Jun 16 | 3,955 | 334 | 1,099 | 1,023 |
| 31 Mar 16 | 3,916 | 299 | 1,098 | 1,030 |
| 31 Dec 15 | 3,876 | 264 | 1,096 | 1,037 |
| 30 Sep 15 | 3,773 | 266 | 1,069 | 999 |
| 30 Jun 15 | 3,670 | 268 | 1,042 | 961 |
| 31 Mar 15 | 3,507 | 192 | 1,011 | 945 |
| 31 Dec 14 | 3,344 | 115 | 980 | 928 |
| 30 Sep 14 | 3,206 | 114 | 963 | 905 |
| 30 Jun 14 | 3,067 | 112 | 946 | 881 |
| 31 Mar 14 | 3,100 | 97 | 971 | 884 |
| 31 Dec 13 | 3,133 | 82 | 996 | 886 |
Quality Earnings: UNC0 has high quality earnings.
Growing Profit Margin: UNC0's current net profit margins (4.4%) are lower than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UNC0's earnings have declined by 17.4% per year over the past 5 years.
Accelerating Growth: UNC0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UNC0 had negative earnings growth (-27.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: UNC0's Return on Equity (2.7%) is considered low.